57.78

1.49% 0.85

After Hours: 57.78

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Royalty Pharma Plc stock is traded at $57.78, with a volume of 2.16M. It is up +1.49% in the last 24 hours and down -1.42% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$56.93

Open:

$57.04

24h Volume:

2.16M

Relative Volume:

0.72

Market Cap:

$25.73B

Revenue:

$2.44B

Net Income/Loss:

$1.36B

P/E Ratio:

30.26

EPS:

1.9093

Net Cash Flow:

$574.14M

1W Performance:

+1.98%

1M Performance:

-1.42%

6M Performance:

+20.63%

1Y Performance:

+60.46%

1-Day Range:

$56.85

$57.92

1-Week Range:

$55.13

$57.92

52-Week Range:

$35.23

$64.38

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	57.78	25.73B	2.44B	1.36B	574.14M	1.9093
VRTX Vertex Pharmaceuticals Inc	507.00	128.50B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	213.74	85.33B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	762.81	78.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	812.30	51.08B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	193.95	41.57B	742.00K	-1.37B	-1.07B	-7.0731

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	UBS	Neutral → Buy
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

01:10 AM

Royalty Pharma EVP Marshall Urist sells $235,594 in shares - Investing.com

01:10 AM

12:58 PM

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com Nigeria

12:58 PM

Oct 08, 2026

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 08, 2026

Oct 05, 2026

At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. - Stock Titan

Oct 05, 2026

Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. - Stock Titan

Oct 05, 2026

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool

Oct 01, 2026

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com South Africa

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Canada

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com UK

Sep 30, 2026

A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan

Sep 30, 2026

4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan

Sep 30, 2026

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Canada

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com South Africa

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com UK

Sep 29, 2026

Sep 28, 2026

Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan

Sep 28, 2026

Sep 27, 2026

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Nigeria

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com UK

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com UK

Sep 25, 2026

Sep 23, 2026